Glutathione Injections: Benefits & What to Expect

Glutathione injections are a compounded, prescription-only form of glutathione, the body’s main intracellular antioxidant, delivered by injection because oral glutathione has very poor systemic availability in humans. They are not FDA-approved, and the U.S. Food and Drug Administration has not evaluated compounded glutathione injections for safety, quality, or efficacy. The human evidence for any specific benefit is limited and mixed, and some of the most widely promoted uses, particularly skin lightening, are explicitly warned against by regulators. This article explains what glutathione injections are, what the actual studies show, and what to expect from a careful, provider-supervised evaluation.

What is glutathione and why is it injected?

Glutathione is a small molecule (a tripeptide of glutamate, cysteine, and glycine) that your cells make and use as their primary antioxidant. The pharmacologic rationale for injecting it comes from a human pharmacokinetic study: after a single oral dose of about 3 g (0.15 mmol/kg) in seven healthy volunteers, plasma glutathione, cysteine, and glutamate did not increase significantly, indicating that oral glutathione’s systemic availability is negligible (Witschi et al., 1992).

That finding explains why clinicians use injectable routes rather than pills. It is not, by itself, evidence that injection produces any clinical, antioxidant, or longevity outcome. It is also worth knowing that when glutathione is given intravenously, it clears the bloodstream quickly: a human PK study in ten healthy volunteers (2 g/m² IV) measured a plasma half-life of about 14.1 ± 9.2 minutes. These are pharmacokinetic facts, not dosing recommendations.

Is glutathione injection FDA-approved?

No. Injectable glutathione is a compounded product, meaning it is prepared by a compounding pharmacy rather than manufactured as an FDA-approved drug. The FDA has not reviewed compounded glutathione injections for safety, quality, or efficacy, and you should not treat them as equivalent to an approved medication.

In June 2022, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8–5 (one abstention) to recommend adding glutathione to the 503A bulk drug substances list. Crucially, the FDA itself had recommended against inclusion, citing serious safety issues such as anaphylaxis and hypersensitivity, hepatotoxicity, and severe wheezing and breathlessness. The PCAC vote is advisory and not binding on the FDA. Even where the FDA exercises interim enforcement discretion for a compounding substance, the agency is explicit that this does not mean it has approved, authorized, or determined the substance is safe.

If you are weighing any compounded therapy, our how it works overview explains how a licensed provider assesses suitability, just as we describe for other compounded options like NAD+ injections.

What benefits does the human evidence actually support?

The honest answer is that rigorous human evidence is sparse and condition-specific. The two most-cited controlled trials illustrate why glutathione cannot be described as broadly “effective.”

Study (human)	Population / design	Dose	Result
Parkinson’s pilot RCT	n=21 (11 glutathione / 10 placebo); randomized, double-blind, placebo-controlled pilot	1,400 mg IV, 3×/week × 4 weeks	Well-tolerated but no statistically significant motor (UPDRS) benefit vs placebo (P=0.32 during treatment)
Cisplatin neuropathy RCT	n=50; advanced gastric cancer on cisplatin; randomized, double-blind, placebo-controlled	Glutathione vs placebo with chemotherapy	Significantly less neuropathy: 4/24 (glutathione) vs 16/18 (placebo) at week 15 (P=0.0001)
Phase-3 RCT (N08CA)	Paclitaxel/carboplatin patients; phase-3 randomized, placebo-controlled	Glutathione vs placebo	Not effective at preventing paclitaxel/carboplatin neuropathy

Read together, these results show how narrow the evidence is. The cisplatin finding was specific to one chemotherapy drug in one cancer population and did not carry over to a different regimen. The Parkinson’s trial, although it confirmed reasonable tolerability at the doses studied, did not demonstrate a motor benefit. None of these figures should be read as a benefit of any particular product, and they cannot be generalized into claims about antioxidant status, “detox,” immunity, or anti-aging.

Can glutathione injections lighten or whiten skin?

This is the use you should be most cautious about. There are essentially no rigorous human clinical trials establishing IV glutathione as an effective or safe skin-lightening agent. A narrative review of the human literature found the evidence unsupported and flagged serious concerns, including anaphylaxis, hepatotoxicity, and the absence of standardized dosing.

Regulators have gone further. The Philippines FDA (Advisory No. 2019-182) warns that IV glutathione used off-label for skin lightening is unapproved and has been linked to Stevens-Johnson syndrome, toxic epidermal necrolysis, thyroid dysfunction, and kidney impairment; there, injectable glutathione is approved only as an adjunct in cisplatin chemotherapy, not for whitening. A separate case report described Stevens-Johnson syndrome / toxic epidermal necrolysis following an IV infusion containing glutathione plus vitamins. Revive does not offer or endorse glutathione for skin lightening.

Why does sourcing and provider oversight matter so much?

Because compounded sterile injectables carry a real, documented contamination risk, the quality of the pharmacy and the supervision of a licensed provider are central, not optional.

In February 2019, the FDA warned compounders not to use glutathione-L-reduced powder distributed by Letco Medical of Decatur, Alabama, to compound sterile injectable drugs. The warning followed an adverse-event cluster: on January 9, 2019, seven patients at an outpatient clinic received IV L-glutathione (200 mg/mL; 7 mL = 1,400 mg each) and within minutes developed nausea, vomiting, lightheadedness, chills, body aches, and sneezing. One patient developed low blood pressure and difficulty breathing and was hospitalized. The FDA attributed the reactions to potentially high endotoxin levels, and noted the powder had reached about 100 compounders in 30 states.

This was not an isolated phenomenon. A separate peer-reviewed public-health investigation documented seven probable cases of endotoxin poisoning from contaminated compounded glutathione infusions (index case 2015, Sydney, Australia), with endotoxin levels in all samples exceeding the accepted pyrogenic threshold of 5 endotoxin units/kg/h. Both clusters reflect sterility and compounding-quality failures, not an inherent property of the glutathione molecule. They are precisely why reputable sourcing, a licensed prescriber, and proper monitoring matter.

What should you expect from a glutathione evaluation?

Expect a clinical conversation, not a guaranteed outcome. A licensed provider should review your goals, medical history, current medications, and relevant labs, and discuss whether any compounded therapy is appropriate for you, what it can and cannot reasonably do, and how you would be monitored. Because the human evidence is preliminary and condition-specific, a careful provider will set realistic, hedged expectations rather than promise results. If you are exploring broader wellness or longevity goals, you may also find our notes on peptides for weight loss useful as a comparison of how compounded therapies are evaluated. Individual results vary, and suitability is determined case by case.

Frequently asked questions

Are glutathione injections FDA-approved?

No. Injectable glutathione is compounded and prescription-only, and it is not FDA-approved. The FDA has not evaluated compounded glutathione injections for safety, quality, or efficacy. In 2022, the FDA itself recommended against adding glutathione to the 503A bulk substances list on safety grounds; a non-binding advisory committee voted 8–5 the other way.

Do glutathione injections help Parkinson’s disease?

The available human evidence does not support that claim. A randomized, double-blind, placebo-controlled pilot trial (n=21; 1,400 mg IV three times weekly for four weeks) found IV glutathione well-tolerated but showed no statistically significant motor benefit versus placebo (P=0.32). This was a small pilot study, and larger trials would be needed to draw firmer conclusions.

Can glutathione injections lighten my skin?

Revive does not offer glutathione for skin lightening, and you should be cautious about that use. There are essentially no rigorous human trials establishing IV glutathione as an effective or safe skin-whitening agent, and regulators including the Philippines FDA warn it has been linked to serious harms such as Stevens-Johnson syndrome, toxic epidermal necrolysis, thyroid dysfunction, and kidney injury.

Are glutathione injections safe?

Safety depends heavily on product quality and provider oversight. The molecule has shown reasonable tolerability at the doses used in some trials, but compounded sterile injectables carry contamination risk: the FDA’s 2019 warning followed an endotoxin-related cluster that harmed seven patients, one hospitalized. Reported safety concerns also include anaphylaxis, hypersensitivity, and hepatotoxicity. A licensed provider should assess your individual suitability and risks.

Why are injections used instead of oral glutathione?

Because oral glutathione has negligible systemic availability in humans. In a pharmacokinetic study of seven healthy volunteers, a single oral dose of roughly 3 g did not significantly raise plasma glutathione. That pharmacologic rationale is why injectable routes are used, but it is not proof that injection produces any specific clinical benefit.

How long does glutathione stay in the blood after an IV?

Not long. In a human pharmacokinetic study of ten healthy volunteers (2 g/m² IV), the plasma half-life was about 14.1 ± 9.2 minutes. This is descriptive PK data and should not be read as a dosing recommendation.